Skip to content
OpenCapital
Get started

Agios Pharmaceuticals AGIO AFS and Trading Securities - Unrealized Loss Position Fair Value

AFS and Trading Securities - Unrealized Loss Position Fair Value at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
——
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
——

Other financials

Income statement

See full
Revenue$20.7M+138%
Gross profit$19.4M+154%
Operating income-$110.0M-3.2%
Net income-$99.1M-11.0%
EPS (diluted)-$1.69-9.0%

Balance sheet

See full
Cash & equivalents$113.6M+43.9%
Total debt$35.7M-32.5%
Total equity$1.1B-24.4%
Total assets$1.2B-23.8%

Cash flow

See full
Operating cash flow-$118.9M-6.7%
CapEx$769.0K+0.4%
Free cash flow-$119.7M-6.6%

Valuation

See full
Market cap$2.12B+18.1%
Enterprise value$2.04B+15.2%
P/S32.1×-16.4×

Profitability

See full
Gross margin90%+2.5pp
Operating margin-720%-204pp
Net margin-639.8%—
FCF margin-582.5%-185pp

Returns & leverage

See full
Return on equity-32.8%—
Debt / equity0×0.0×
Current ratio14.2×-4.3×

Where this comes from

Reported directly by Agios Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition.

The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Agios Pharmaceuticals's afs and trading securities - unrealized loss position fair value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Agios Pharmaceuticals's AFS and trading securities - unrealized loss position fair value?
Agios Pharmaceuticals (AGIO) reported AFS and trading securities - unrealized loss position fair value of $461.4M in Q1 2026.
How has Agios Pharmaceuticals's AFS and trading securities - unrealized loss position fair value changed year-over-year?
Agios Pharmaceuticals's AFS and trading securities - unrealized loss position fair value decreased by 21.4% year-over-year, from $586.9M to $461.4M.
What is the long-term trend for Agios Pharmaceuticals's AFS and trading securities - unrealized loss position fair value?
Over 5 years (2020 to 2025), Agios Pharmaceuticals's AFS and trading securities - unrealized loss position fair value has grown at a -14.6% compound annual growth rate (CAGR), from $299M to $136.2M.